Verona Pharma appoints Novartis Gene Therapies VP Lisa Deschamps to its board

pharmafile | March 2, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, verona, verona pharma 

Verona Pharma has appointed Lisa Deschamps, Senior Vice President and Chief Business Officer of Novartis Gene Therapies, as Non-Executive Director on their board.

In her role at Novartis, Deschamps is responsible for strategic planning and worldwide commercialisation of pipeline and in-market assets across the company’s gene therapy portfolio. This includes managing significant revenue growth targets and profitability margins globally.

Deschamps also serves on a number of other commercial and development executive teams within the Novartis enterprise.

Throughout her tenure, Deschamps has gained significant global and US experience in bringing respiratory and other specialised therapeutic products to market. In addition, she has extensive experience in the exploration of potential acquisition and partnering opportunities.

Dr David Ebsworth, Chairperson of Verona Pharma, said: “We are delighted to welcome Lisa to the Board. Her wealth of leadership, strategic and commercial expertise will be valuable as we progress ensifentrine through Phase III trials and prepare for commercialisation.”

Verona’s ensifentrine is a treatment for respiratory diseases such as COPD, COVID-19, asthma and cystic fibrosis. The company began Phase III trials to test its efficacy in the treatment of COPD in September last year.

Related Content

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …


Verona Pharma submits FDA New Drug Application for COPD treatment

UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content